Publications by authors named "Momoko Nishikori"

Introduction: Patients undergoing chimeric antigen receptor (CAR) T-cell therapy face prolonged treatment timelines and are prone to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after infusion. Disabilities in physical function and the importance of rehabilitation during CAR-T-cell therapy to maintain physical function have been poorly documented.

Method: We performed a retrospective cohort study to assess changes in exercise tolerance via differences in a 6-min-walking distance (Δ6MWD) and factors influencing it.

View Article and Find Full Text PDF

The linear ubiquitin chain assembly complex (LUBAC) plays crucial roles in NF-κB signaling and protection against cell death by generating linear ubiquitin chains. Its accessory subunits, HOIL-1L and SHARPIN, regulate LUBAC function by binding to ubiquitin chains via their Npl4 zinc finger (NZF) domains. However, the synergistic effects of the two NZF domains on LUBAC function remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • This study is a follow-up on the effectiveness and safety of tazemetostat for Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) who have the EZH2 mutation, after a median follow-up of 35 months.
  • The FL cohort had an impressive objective response rate of 70.6%, with significant progression-free survival (PFS) rates at 24 and 36 months (72.1% and 64.1% respectively), while no unexpected severe adverse events were reported.
  • Overall, long-term treatment with tazemetostat appears to be a promising and safe option as a third-line or later therapy for patients with this specific
View Article and Find Full Text PDF
Article Synopsis
  • Somatic hypermutations (SHMs) in the immunoglobulin heavy chain (IgH) gene are common in diffuse large B-cell lymphoma (DLBCL) and are known to result in immunogenic neoantigens, but their prognostic impact hasn't been extensively studied.
  • The BIOMED-2 PCR protocol, a standard for analyzing lymphoid malignancies, can miss some cases due to these SHMs, prompting the design of three primer sets to enhance detection.
  • A study of 301 DLBCL patients showed that complete detection of IgH V PCR patterns via this improved approach correlated with worse overall survival and progression-free survival compared to patients with different patterns, indicating its potential utility in clinical prognosis.
View Article and Find Full Text PDF

Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for B cell malignancies. A certain fraction of patients, however, experience post-CAR-T relapse, and due to the difficulty of precise relapse prediction, biomarkers that can predict the strength and duration of CAR-T efficacy are needed before CAR-T infusion. Therefore, we performed a single-center cohort study including 91 diffuse large B cell lymphoma (DLBCL) patients treated with CAR-T in order to identify such a new prognostic biomarker.

View Article and Find Full Text PDF

Follicular lymphoma (FL), the most common indolent B-cell lymphoma, develops over decades before manifesting as overt disease. BCL2 overexpression by t(14;18) confers a survival advantage to B cells during the germinal center reaction, and abnormalities in epigenetic modifier genes lead to desynchronization of gene expression changes in germinal center B cells. Studies in mouse models have shown that BCL2 overexpression and epigenetic deregulation in B cells cooperatively promote lymphomagenesis.

View Article and Find Full Text PDF

Response determined by 18[F]-fluoro-2-deoxy-D-glucose (F-FDG) positron emission tomography (PET)-CT after induction therapy can predict progression-free survival (PFS) in follicular lymphoma (FL). However, little prospective research has examined the significance of PET after second-line therapy. We conducted a prospective multicenter phase II trial (W-JHS NHL01) of bendamustine plus rituximab (BR) without rituximab maintenance for FL in first relapse.

View Article and Find Full Text PDF

Prolonged hematotoxicity is the most common long-term adverse event in chimeric antigen receptor T cell therapy (CAR-T). To evaluate the impact on prolonged cytopenia of inflammatory status after CAR T infusion, we performed a single-center retrospective study and analyzed patients with B cell lymphomas after CAR-T. Among 90 patients analyzed at 90 days after infusion, the cumulative incidence was 57.

View Article and Find Full Text PDF
Article Synopsis
  • Subacute myelopathy is a rare but severe side effect of methotrexate (MTX) that can lead to paraplegia, with homocysteine potentially playing a role in its development.
  • A case study involves a 34-year-old woman with diffuse large B-cell lymphoma who experienced progressive paraplegia and bladder/bowel dysfunction after receiving a chemotherapy regimen that included high-dose MTX.
  • Symptoms improved significantly within 4.5 months after receiving a treatment combination of S-adenosylmethionine, methionine, cyanocobalamin, and folate, highlighting the need for careful monitoring and early intervention during high-dose MTX treatment.
View Article and Find Full Text PDF
Article Synopsis
  • - Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a global phase II trial (EPCORE NHL-1), demonstrating deep and lasting responses with manageable side effects.
  • - The phase I/II trial (EPCORE NHL-3) focused on Japanese patients with R/R CD20 B-cell non-Hodgkin's lymphoma who had received two or more prior treatments, revealing an overall response rate of 55.6% and a complete response rate of 44.4% at a median follow-up of 8.4 months after receiving subcutaneous epcoritamab.
View Article and Find Full Text PDF
Article Synopsis
  • Optimized management of citrate-induced hypocalcemia enhances the safety of leukapheresis, a procedure used for cytotherapy, by monitoring serum ionized calcium levels throughout the process.
  • A study with 76 patients found that a large number experienced fluctuating hypercalcemia post-leukapheresis, which was influenced by factors like blood volume processed relative to body weight and the speed of calcium supplementation.
  • Researchers created a formula to predict serum calcium levels after leukapheresis, recommending that in cases of high blood volume processing, slowing down the procedure can help prevent hypocalcemia without causing high calcium levels afterward.
View Article and Find Full Text PDF

DUSP22-rearranged primary cutaneous anaplastic large-cell lymphoma (pcALCL) has a biphasic histological pattern defined by large dermal atypical lymphocytes and epidermotropic small lymphocytes resembling pagetoid reticulosis, but the positivity rate of the biphasic pattern in DUSP22-rearranged pcALCL is unknown. Immunohistochemically, LEF1 expression in >75% of tumor cells is associated with DUSP22-rearrangement (DUSP22-R) in systemic ALCL. However, whether this association applies to pcALCL remains unclear.

View Article and Find Full Text PDF

Acute kidney injury (AKI) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of multiple antimicrobials is one of the major causes of post-transplantation AKI, owing to the potential nephrotoxicity of each agent and of drug-drug interactions (DDIs). No satisfactory reports on DDIs the field of allo-HSCT have been published.

View Article and Find Full Text PDF
Article Synopsis
  • Small lymphocytic lymphoma (SLL) is a rare type of lymphoma closely related to chronic lymphocytic leukemia (CLL), characterized by growth primarily in lymph nodes and spleen without lymphocytosis.
  • The report discusses two SLL patients who also developed lung cancer, sharing similar biological traits like trisomy 12 and the absence of lymphocytosis or cytopenia.
  • One patient experienced a worsening of SLL symptoms after receiving immunochemotherapy that included nivolumab and ipilimumab, suggesting potential complications and a link between SLL and lung cancer when using immune checkpoint inhibitors.
View Article and Find Full Text PDF

Antibody-mediated rejection (AMR) is a refractory rejection after ABO blood-type incompatible (ABOi) or donor-specific antibody (DSA)-positive liver transplantation (LT). Pretransplant rituximab desensitization dramatically reduced posttransplant AMR development; however, risk factors for AMR in the rituximab era remain unclear in both ABOi living-donor LT (ABOi-LDLT) and preformed DSA-positive LT (pDSA-LT). Of our 596 adult LDLTs (≥18 y) after rituximab introduction (2004-2019), 136 were ABOi-LDLT (22.

View Article and Find Full Text PDF

Prediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker.

View Article and Find Full Text PDF

Purpose: Upregulation of type I interferon (IFN) signaling has been increasingly detected in inflammatory diseases. Recently, upregulation of the IFN signature has been suggested as a potential biomarker of IFN-driven inflammatory diseases. Yet, it remains unclear to what extent type I IFN is involved in the pathogenesis of undifferentiated inflammatory diseases.

View Article and Find Full Text PDF

Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown.

View Article and Find Full Text PDF

Genes that regulate immunological activities are transiently suppressed by epigenetic modification during the germinal center reaction of B cells and reactivated when B cells exit the germinal center. Mutations of EZH2 and other epigenetic modifier genes are frequently involved in the pathogenesis of follicular lymphoma and lead to silencing of the genes necessary for exiting the germinal center. Tazemetostat, an EZH2 inhibitor, has been approved for the treatment of follicular lymphoma with EZH2 gain-of-function mutations in Japan.

View Article and Find Full Text PDF

Background: The oncofetal protein insulin-like growth factor 2 mRNA binding protein-3 (IMP3) is expressed in various cancers. In this study, we examined the diagnostic utility of IMP3 immunohistochemistry in the context of intravascular large B-cell lymphoma (IVL).

Methods: We obtained 25 skin biopsy (SB) specimens diagnosed as IVL and nine IVL-negative SB specimens from 27 IVL patients.

View Article and Find Full Text PDF